EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Abstract excerpt

With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) is a well-recognized and effective target for NSCLC therapies, targeted EGFR therapy with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has achieved ideal clinical efficacy in recent years. Unfortunately,...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Carcinoma, Non-Small-Cell Lung
• Drug Resistance, Neoplasm
• ErbB Receptors
• Lung Cancer Treatments and Mutations